Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024
April 24 2024 - 6:00AM
Business Wire
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions
company with a focus in lung disease, announced today that it will
release financial results for the first quarter ended March 31,
2024 after the close of trading on Wednesday, May 8. Biodesix’s
management will host a conference call and webcast to discuss its
financial results and provide a general business update at 4:30
p.m. Eastern Time on the same day.
Listeners can register for the webcast via this link. Analysts
who wish to participate in the question and answer session should
use this link. A replay of the webcast will be available via the
company’s investor website approximately two hours after the call’s
conclusion. Participants are advised to join 15 minutes prior to
the start time.
About Biodesix
Biodesix is a leading diagnostic solutions and services company
with a focus in lung disease. The Company develops diagnostic tests
addressing important clinical questions by combining multi-omics
through the power of artificial intelligence. Biodesix offers five
Medicare-covered tests for patients with lung diseases. The
blood-based Nodify Lung® Nodule Risk Assessment testing strategy,
consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates
the risk of malignancy in incidental pulmonary nodules, enabling
physicians to better triage patients to the most appropriate course
of action. The blood based IQLung™ strategy for lung cancer
patients integrates the GeneStrat® targeted ddPCR™ test, the
GeneStrat NGS® test and the VeriStrat® test to support treatment
decisions across all stages of lung cancer with results in an
average of two to three business days, expediting the time to
treatment. Biodesix collaborates with many of the world’s leading
biotechnology and pharmaceutical companies to solve complex
diagnostic challenges in lung disease. For more information, visit
biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release other
than statements of historical fact, are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of backlog and the timing and assumptions
regarding collection of revenues on projections, availability of
funds and future capital including under the term loan facility,
expectations regarding revenue and margin growth and its impact on
profitability, and the impact of a pandemic, epidemic, or outbreak,
including the COVID-19 pandemic, on Biodesix and its operations and
financial performance. Forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be
predicted or quantified. The Company's ability to continue as a
going concern could cause actual results to differ materially from
those contemplated in this press release and additionally, other
factors that could cause actual results to differ materially from
those contemplated in this press release can be found in the Risk
Factors section of Biodesix most recent annual report on Form 10-K,
filed March 1, 2024. Biodesix undertakes no obligation to revise or
publicly release the results of any revision to such
forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240424927787/en/
Media: Natalie St. Denis Natalie.StDenis@biodesix.com
1-720-925-9285
Investors: Chris Brinzey chris.brinzey@westwicke.com
(339) 970-2843
Biodesix (NASDAQ:BDSX)
Historical Stock Chart
From Apr 2024 to May 2024
Biodesix (NASDAQ:BDSX)
Historical Stock Chart
From May 2023 to May 2024